Form 4: Amgen CEO Robert Bradway Executes Stock Transaction
Statement of Changes in Beneficial Ownership
Amgen Chairman and CEO Robert A. Bradway reported the disposition of 2,079 shares of common stock to cover tax obligations.
Summary
- Robert A. Bradway, Chairman, CEO and President of Amgen Inc., disposed of 2,079 shares of common stock.
- The transaction occurred on May 7, 2026, at a price of $331.11 per share.
- The disposition was executed via code 'F', indicating a payment of tax liability by delivering or withholding securities.
- Following this transaction, the reporting person maintains direct beneficial ownership of 505,160 shares.
- Indirect holdings remain unchanged, including 60,060 shares in a GRAT, 60,060 shares in a Spousal GRAT, and 29,940 shares held by his spouse.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a mandatory administrative action for tax purposes and does not indicate a change in the executive's outlook on the company.
Positives
- The transaction was a routine tax withholding event rather than an open-market sale, signaling no change in long-term confidence.
Negatives
- Reduction in direct share ownership by 2,079 shares.
Risks
- None identified; this is a standard regulatory disclosure for executive tax obligations.
Future Outlook
Not applicable; this is a retrospective disclosure of an insider transaction.
Industry Context
StockSavvy.ai notes that routine tax-related dispositions by C-suite executives in the biotechnology sector are standard practice and generally do not reflect shifts in corporate strategy or internal sentiment.
Comparison to Industry Standards
- The transaction aligns with standard executive compensation and tax management practices observed at large-cap pharmaceutical companies like Pfizer, Merck, and Gilead.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a routine tax-related disposition.
Next Steps
- None
Key Dates
| Date | Description |
|---|---|
| 05/07/2026 | Date of the reported stock transaction. |
| 05/08/2026 | Date of filing the Form 4. |
Keywords
Amgen, AMGN, Insider Trading, Form 4, Robert Bradway, Biotech, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.